Treatment with interferons (including pegylated interferons) in patients with hepatitis B

Cooksley, W. Graham (2004). Treatment with interferons (including pegylated interferons) in patients with hepatitis B. In: P. D. Berk, Seminars in liver disease: Proceedings of the Scientific and Clinical Expert Panel Meeting on HBV Viral Kinetics and Clinical Management. Scientific and Clinical Expert Panel Meeting on HBV Viral Kinetics and Clinical Management, Chicago, IL, U. S. A., (45-53). 18 October, 2003. doi:10.1055/s-2004-828678


Author Cooksley, W. Graham
Title of paper Treatment with interferons (including pegylated interferons) in patients with hepatitis B
Conference name Scientific and Clinical Expert Panel Meeting on HBV Viral Kinetics and Clinical Management
Conference location Chicago, IL, U. S. A.
Conference dates 18 October, 2003
Proceedings title Seminars in liver disease: Proceedings of the Scientific and Clinical Expert Panel Meeting on HBV Viral Kinetics and Clinical Management   Check publisher's open access policy
Journal name Seminars in Liver Disease   Check publisher's open access policy
Place of Publication New York, N.Y. U.S.A.
Publisher Thieme-Stratton
Publication Year 2004
Sub-type Fully published paper
DOI 10.1055/s-2004-828678
ISSN 0272-8087
Editor P. D. Berk
Volume 24
Issue Supp. 1
Start page 45
End page 53
Total pages 9
Language eng
Abstract/Summary Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents. Therefore, the recent European Association for the Study of the Liver (EASL) Consensus Committee recommended the use of interferon alpha for this condition. Treatment with pegylated interferons in several trials has shown better results still. Lamivudine in combination with interferon, however, did not improve the results at 6 months after the end of therapy. In HBeAg-negative chronic HBV infection, pegylated interferon alpha is superior to lamivudine, and, again, combination with lamivudine does not improve the results. Side effects in all studies have been tolerable. Thus, these observations in chronic HBV infection, whether HBeAg-positive or HBeAg-negative, suggest an important, even primary, role for pegylated interferon therapy.
Subjects C1
321010 Infectious Diseases
730101 Infectious diseases
Keyword Gastroenterology & Hepatology
Interferon
Pegylated Interferon Alfa-2a (40 Kd)
Pegylated Interferon Alfa-2b (12 Kd)
Term Follow-up
Alpha-interferon
E-antigen
Virus-infection
Untreated Patients
Positive Patients
Therapy
Alfa
Combination
Lamivudine
Q-Index Code C1

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 47 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 64 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 03:40:12 EST